Avicanna 

Avicanna Inc., a commercial-stage and international biopharmaceutical company, focuses on the development, advancement, and commercialization of evidence-based cannabinoid-based products for worldwide consumers and for medical and pharmaceutical market segments. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes advanced research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products, such as oral, sublingual, topical, and transdermal deliveries under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and feminized and standardized seeds, resins or whole plant crude oils, cannabinoid distillates, and isolated cannabinoids and bulk formulations under the Aureus brand. It also offers cannabidiol, cannabigerol, and tetrahydrocannabinol seeds under the Avesta Genetica brand name. In addition, the company is developing pharmaceutical products for epidermolysis bullosa, eczema, acne, anxiety and depression, sleep disorders, opioid addiction, epilepsy, Parkinson's disease, multiple sclerosis, chronic pain, neuropathic pain, arthritis, and palliative care diseases. Avicanna has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.